Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gan & Lee Insulins Data Is Boon For Sandoz

Three Biosimilar Candidates Meet Primary Analyses

Jul 05 2021

• By Dean Rudge

Insulin — Gan & Lee welcomed a "major milestone" • Source: Shutterstock

Related Content

Sandoz Forms Insulin Biosimilars Deal With Gan & Lee

Dec 19 2018

Sandoz Aims For $6bn Biosimilar Business By 2030

Nov 27 2020

Sandoz And Polpharma Strike Global Deal For Natalizumab

Sep 04 2019

Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways

Jun 22 2021

Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July

May 13 2021

Sandoz’s Saynor Sees Tipping Point For Biosimilars

Jul 05 2021

Biocon And Viatris Scoop EU Insulin Aspart Approval

Feb 15 2021

Related Companies

Sandoz Inc.

Additional Topics

Biosimilars Clinical Trials Strategy Diabetic Care BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window